China
Africa
Explore chapters and articles related to this topic
Antineoplastic Drugs during Pregnancy
Published in “Bert” Bertis Britt Little, Drugs and Pregnancy, 2022
Vinblastine (Velban, Velsar) is approved to treat lymphoma, Hodgkin’s disease, chronic myelocytic leukemia, and several carcinomas (breast, bladder, lung, and testis). Review of five case reports of pregnant women with Hodgkin’s disease gave details of 13 normal infants born after prenatal exposure to vinblastine. Eleven infants were exposed to vinblastine during the first trimester while two were exposed in the second trimester. Among the offspring exposed to vinblastine during the first trimester, congenital anomalies were observed in two infants, one spontaneous abortion occurred, and two normal infants were born at term (Metz et al., 1989). In one cohort of 27 infants exposed to vinblastine anytime during pregnancy, no anomalies were reported. Among 17 infants exposed only during the first trimester, no birth defects were noted (Aviles and Neri, 2001; Wiebe and Sipila, 1994). In another case report, there was one normal infant whose mother was exposed to vinblastine, bleomycin, and cisplatin therapy during the second trimester to treat malignant teratoma (Christman et al., 1990). It is important to note there is considerable overlap in the published reports included in the different reviews. Among 134 women treated with doxorubicin, bleomycin, vinblastine, and dacarbazine during pregnancy, no congenital anomalies were reported. However, only seven were exposed during the first trimester (Maggen et al., 2019). Vinblastine was associated with an increased frequency of congenital anomalies in rats, mice, hamsters, and rabbits exposed during embryogenesis (Manufacturer’s information).
Vinca rosea (Madagascar Periwinkle) and Adhatoda vesica (Malabar Nut)
Published in Azamal Husen, Herbs, Shrubs, and Trees of Potential Medicinal Benefits, 2022
Rajib Hossain, Md Shahazul Islam, Dipta Dey, Muhammad Torequl Islam
Vinblastine, vincristine, vindoline, vindolidine, vindolicine, vindolinine, and vindogentianine are a class of alkaloids in V. rosea that have already been discovered to have chemotherapeutic effects (Cragg and Newman, 2003; Tiong et al., 2013; 2015). They exhibited antiproliferation characteristics via altering microtubular dynamics and enhancing apoptosis (Almagro et al., 2015). The first plant-derived chemotherapeutic agent to be used in clinical trials were vinblastine and vincristine (Cragg and Newman, 2003). Vinblastine sulfate is used to treat acute and chronic leukemia, Hodgkin's disease, lymphosarcoma, choriocarcinoma, neuroblastoma, and carcinomas. Vincristine sulfate is an oxidized version of vinblastine (Almagro et al., 2015; Aslam et al., 2010).
Chemotherapy in pregnancy
Published in Hung N. Winn, Frank A. Chervenak, Roberto Romero, Clinical Maternal-Fetal Medicine Online, 2021
Vinblastine is also a vinca alkaloid derived from the periwinkle plant. It is indicated for the treatment of HL and NHL, breast cancer, Kaposi’s sarcoma, and renal cell carcinoma. It exerts its antitumor effect by inhibiting tubulin polymerization and disrupting microtubules during the M-phase of the cell cycle. As with most agents described here, animal studies in early pregnancy have demonstrated increased resorption, spontaneous abortion, and gross fetal abnormalities. However, some human studies have reported no teratogenic effects from first-trimester exposure (90). At 18 weeks of gestation, a patient was diagnosed with an endodermal sinus tumor of the ovary, and following laparotomy, she received three courses of cisplatin, vinblastine, and bleomycin (69). She delivered a healthy and normal infant at 31 weeks. To date, there have been more than half a dozen other patients who have received vinblastine in combination regimens, followed by the delivery of normal, healthy infants (91,92).
Delivery of vinblastine-containing niosomes results in potent in vitro/in vivo cytotoxicity on tumor cells
Published in Drug Development and Industrial Pharmacy, 2018
Boshra Amiri, Hasan Ahmadvand, Ali Farhadi, Aazam Najmafshar, Mohsen Chiani, Dariush Norouzian
Vinca alkaloids such as vinblastine are a class of antitumor agents used for treatment of many kinds of cancers; however, their clinical application is restricted because of side effects and multidrug resistance. The aim of this study was to increase the therapeutic efficacy of vinblastine through drug delivery systems. Drug delivery using niosomal vinblastine displayed sustained release behavior, greater in vitro cytotoxicity, higher tumor growth inhibitory effect than free vinblastine, thus enhanced the therapeutic efficiency of the loaded drug. Therefore, PEGylated niosomes as drug carriers could be one of the promising drug delivery systems to deliver anti-cancer drugs to tumor cells. Further research using targeted niosomes have been planned for future studies.
Vinblastine loaded on graphene quantum dots and its anticancer applications
Published in Journal of Microencapsulation, 2022
Thi Hang Au, Bich Ngoc Nguyen, Phuong Hoa Nguyen, Stephanie Pethe, Giang Vo-Thanh, Thu Ha Vu Thi
Vinblastine (Vin) is one of the drugs used for chemotherapy. It is an indole alkaloid obtained from the Madagascan periwinkle plant, Catharanthus roseus (Family Apocynaceae), formerly called Vinca rosea L (Agrawal 2007). Vinblastine is used as a chemotherapy drug for Hodgkin's disease and various cancers such as ovarian cancer, non-Hodgkin's lymphomas, breast cancer, head and neck cancer, Kaposi's sarcoma, renal cell cancer, and testicular cancer (Bánóczi et al.2010). Vinblastine has a high economic value, however, is expensive, and its production is limited to low quantities (Ribatti et al.2003, Amiri et al.2018, Radakovic and Boger 2019).
Revisiting the management of chronic ITP; a randomized controlled clinical trial
Published in Platelets, 2021
Ghada E. M. Abdallah, Esam A. S. Elbiih, Douaa Sayed, Sawsan M. Moeen, Shima Gafer, Ahmad F. Thabet
There was a single clinical trial comparing the efficacy of vinblastine by two different methods of administration. The response rate in chronic ITP was comparable between the two groups with a rate of overall response ranging from 50% to 77% [17]. Also, three prospective studies showed an overall response rate range from 65% to 75% [14,17,18].In our study, the highest response rate was achieved in the 12 weeks-visit where 72.5% achieve overall response and 2.5% complete response. There was one patient relapsed after achieving a response in the Azathioprine group and six patients in the Vincristine group. No relapse occurred in the Hydroxychloroquine group.